Pharvaris Q2 2026 loss widens as company cites higher clinical and commercial buildout costs
PHVS•Q2 loss widens on higher operating expenses
Pharvaris posted a Q2 2026 loss of EUR 47.84 million as operating expenses rose 26% to EUR 50.79 million.
R&D spending climbed 18% to EUR 35 million, driven by higher clinical activity, personnel costs and licensing fees.
Clinical costs rose on IR extension, XR long-term open-label work and CREAATE in acquired angioedema, offset by RAPIDe-3 completion.
G&A rises on commercial buildout and cash position
G&A expenses increased 47% to EUR 15.79 million on commercial hiring, higher professional fees and conference spending supporting a potential IR launch.
Cash and cash equivalents totaled EUR 318.28 million at June 30, 2026, supported by a May equity offering that raised net EUR 105.7 million.
